In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.
By Joseph Burns
Advertisement
Articles by By Joseph Burns
Advertisement
Latest Updated Articles
COME HOME Program Set to Save $33.5M Over 3 YearsPublished: August 25th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5